Hostname: page-component-745bb68f8f-v2bm5 Total loading time: 0 Render date: 2025-02-03T00:28:13.099Z Has data issue: false hasContentIssue false
  • English
  • Français

The Prolonged Anticonvulsant Action of Taurine on Genetically Determined Seizure-Susceptibility

Published online by Cambridge University Press:  18 September 2015

R. Huxtable  and
H. Laird
R. Huxtable*
Affiliation:
Departments of Pharmacology and Pharmacology & Toxicology, University of Arizona, Tucson, Arizona
H. Laird
Affiliation:
Departments of Pharmacology and Pharmacology & Toxicology, University of Arizona, Tucson, Arizona
*
Department of Pharmacology, University of Arizona, Tucson, Arizona, 85724, U.S.A.
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

A prolonged anticonvulsant action of taurine has been shown in a strain of seizure susceptible rats. The audiogenic rat (AS) has lower intracerebral electroshock thresholds in three auditory nuclei; the ventral cochlear, the inferior colliculi and the medial geniculate, and in one nonauditory structure; the reticular formation, than a strain of nonaudiogenic rats (NAS). Furthermore, the AS animals routinely display maximal (tonic-clonic) convulsion, regardless of brain structure stimulated, whereas NAS subjects respond with minimal (clonic) convulsions. Within three minutes of intraventricular injection of 8 μ moles, taurine reduces the susceptibility of AS rats to intracerebral electroshock seizures along with attenuation of the severity of the convulsion. The initial elevation in intracerebral electroshock threshold returns to pretreatment value at 24 hours, only to rise again at 48 hours and to remain elevated through day six after injection. In contrast, the severity of convulsions remains attenuated through 24 hours, after which it returns to pre-injection level. By comparison, NAS animals injected intracerebroventricularly in an identical fashion to the AS rats showed no changes in either seizure threshold or severity of convulsion. The direct injection of 200n-moles of taurine in the inferior colliculi of AS rats produced a slow developing, but prolonged, elevation of intracerebral electroshock threshold of this auditory nuclei. However, at no time after the intracerebral injection of taurine was convulsive severity changed. Injection of taurine into the inferior colliculi of NAS subjects did not change either susceptibility or severity of intracerebral electroshock seizures. The data indicate that taurine produces an anticonvulsant effect which is slow in onset, potent, selective and prolonged.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 5 , Issue 2 , May 1978 , pp. 215 - 221
Copyright
Copyright © Canadian Neurological Sciences Federation 1978

References

REFERENCES

Bergamini, L., Mutani, R., Delsedine, M. and Durelli, L., (1974). First clinical experience on the antiepileptic action of taurine. European Journal of Neurology, 11, 261–269.CrossRefGoogle ScholarPubMed
Izumi, K., Donaldson, J., Minnich, J.L., and Barbeau, A., (1973). Ouabain-induced seizures in rats: Suppressive effects of taurine and γ-amino-butyric acid. Canadian Journal of Physiology and Pharmacology, 51, 885–889.CrossRefGoogle Scholar
Jobe, P., Picchioni, A., and Chin, L., (1973). Role of brain norepinephrine in audiogenic seizure in the rat. Journal of pharmacology and Experimental Therapeutics, 184, 1–10.Google ScholarPubMed
Joseph, M., and Emson, P., (1976). Taurine and cobalt induced epilepsy in the rat: A biochemical and electrocorticographic study. Journal of Neurochemistry, 27, 1495–1501.CrossRefGoogle Scholar
Krnjevic, K. and Puil, E., (1976). Electrophysiological studies on actions of taurine. In: Taurine (Huxtable, R., and Barbeau, A., eds.), Raven Press, New York, N.Y., pp. 179–189.Google Scholar
Laird, H., and Huxtable, R., (1976). Effect of taurine on audiogenic seizure response in rats. In: Taurine, (Huxtable, R., and Barbeau, A., eds.). Raven Press, New York, N.Y., pp. 267–274.Google Scholar
Laird, H., and Huxtable, R., (1978). Taurine and audiogenic epilepsy. In: Taurine and Neurological Disorders (Barbeau, A., and Huxtable, R., eds.). Raven Press, N.Y., pp. 339–357.Google Scholar
Mutani, R., Bergamini, L., Fariello, R. and Delsedime, M., (1974). Effects of taurine on cortical acute epileptic foci. Brain Research, 70, 170–173.CrossRefGoogle ScholarPubMed
Steel, R.. and Torrie, J., ( 1960). Principles and procedures of statistics. McGraw-Hill Book Company Inc.. New York.Google Scholar
Takahashi, R., and Nakane, Y., (1978). Clinical trial of taurine in epilepsy. In: Taurine and Neurological Disorders. (Bar-beau, A., and Huxtable, R., eds.). Raven Press. New York. N.Y. In Press.Google Scholar
van Gelder, N.. (1972). Antagonism by taurine of cobalt induced epilepsy in cat and mouse. Brain Research, 47, 157–165.CrossRefGoogle ScholarPubMed
van Gelder, N. (1976). Rectification of abnormal glutamic acid levels by taurine. In: Taurine. (Huxtable, R. and Barbeau, A., eds.), Raven Press. New York. N.Y.. pp. 293–302.Google Scholar
van Gelder, N.. Sherwin, A., Sacks, C. and Anderman, F. (1975). Biochemical observations following administration of taurine to patients with epilepsy. Brain Research. 94, 297–306.CrossRefGoogle ScholarPubMed